U.S. market Closed. Opens in 2 days 3 hours 23 minutes

PBYI | Puma Biotechnology, Inc. Stock Overview

(Stock Exchange: NASDAQ)
Day's Range 3.74 - 4.03
52 Week Range 2.1300 - 7.73
Beta 1.31
Implied Volatility 299.55%
IV Rank 79.87%
Day's Volume 357,108
Average Volume 475,672
Shares Outstanding 48,238,800
Market Cap 184,754,604
Sector Healthcare
Industry Biotechnology
IPO Date 2012-04-24
Valuation
Profitability
Growth
Health
P/E Ratio 11.97
Forward P/E Ratio N/A
EPS 0.32
1YR Price Target N/A
Dividend Yield N/A
Dividend Per Share N/A
Dividend ExDate N/A
Dividend PayDate N/A
Employees 185
Country USA
Website PBYI
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for the use of neratinib in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer; PB272 (neratinib, oral) for HER2 mutation-positive solid tumors. It has a license agreement with Pfizer, Inc.; and sub-license agreement with Specialised Therapeutics Asia Pte Ltd., CANbridge BIOMED Limited, Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.
*Chart delayed
Analyzing fundamentals for PBYI we got that it has average fundamentals where Valuation is considered to be slightly undervalued, Profitability is poor, Growth is very good and Health is frighteningly weak. For more detailed analysis please see PBYI Fundamentals page.

Watching at PBYI technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, but short-term trend is bullish. More technicals details can be found on PBYI Technicals page.
An error has occurred. This application may no longer respond until reloaded. Reload 🗙